Skip to main content
. Author manuscript; available in PMC: 2016 Aug 31.
Published in final edited form as: Medchemcomm. 2013 Dec 13;5(3):255–267. doi: 10.1039/C3MD00288H

Fig. 5. Luciferin architectures for improved bioluminescence imaging.

Fig. 5

(A) Examples of heterocyclic analogues of D-luciferin that exhibit altered bioluminescent emission spectra. (B) Luciferin–fluorophore conjugates also exhibit red-shifted emissions. (C) Chemical structures of three luciferins that exhibit robust emission with various luciferases.